Literature DB >> 20000863

EIDOS: a mechanistic classification of adverse drug effects.

Robin E Ferner1, Jeffrey K Aronson.   

Abstract

The mechanisms of adverse drug effects have not been adequately classified. Here, we propose a comprehensive mechanistic classification of adverse drug effects that considers five elements: the Extrinsic chemical species (E) that initiates the effect; the Intrinsic chemical species (I) that it affects; the Distribution (D) of these species in the body; the (physiological or pathological) Outcome (O); and the Sequela (S), which is the adverse effect. This classification, which we have called EIDOS, describes the mechanism by which an adverse effect occurs; it complements the DoTS classification of adverse effects (based on clinical pharmacology), which takes into account Dose responsiveness, Time course, and Susceptibility factors. Together, these two classification systems, mechanistic and clinical, comprehensively delineate all the important aspects of adverse drug reactions; they should contribute to areas such as drug development and regulation, pharmacovigilance, monitoring therapy, and the prevention, diagnosis, and treatment of adverse drug effects.

Mesh:

Year:  2010        PMID: 20000863     DOI: 10.2165/11318910-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  43 in total

1.  Fanconi syndrome (adult type) developing secondary to the ingestion of outdated tetracycline.

Authors:  J M GROSS
Journal:  Ann Intern Med       Date:  1963-03       Impact factor: 25.391

Review 2.  Clarification of terminology in drug safety.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.

Authors:  Torbjörn Callréus
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Medication errors: what they are, how they happen, and how to avoid them.

Authors:  J K Aronson
Journal:  QJM       Date:  2009-05-20

5.  Adverse biochemical and clinical consequences of furosemide administration.

Authors:  M Spino; E M Sellers; H L Kaplan; C Stapleton; S M MacLeod
Journal:  Can Med Assoc J       Date:  1978-06-24       Impact factor: 8.262

6.  Outbreak of adverse reactions associated with contaminated heparin.

Authors:  David B Blossom; Alexander J Kallen; Priti R Patel; Alexis Elward; Luke Robinson; Ganpan Gao; Robert Langer; Kiran M Perkins; Jennifer L Jaeger; Katie M Kurkjian; Marilyn Jones; Sarah F Schillie; Nadine Shehab; Daniel Ketterer; Ganesh Venkataraman; Takashi Kei Kishimoto; Zachary Shriver; Ann W McMahon; K Frank Austen; Steven Kozlowski; Arjun Srinivasan; George Turabelidze; Carolyn V Gould; Matthew J Arduino; Ram Sasisekharan
Journal:  N Engl J Med       Date:  2008-12-03       Impact factor: 91.245

Review 7.  Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.

Authors:  A Knight; J Askling; F Granath; P Sparen; A Ekbom
Journal:  Ann Rheum Dis       Date:  2004-05-06       Impact factor: 19.103

8.  Phenoxybenzamine is more potent in inactivating alpha 1- than alpha 2-adrenergic receptor binding sites.

Authors:  K P Minneman
Journal:  Eur J Pharmacol       Date:  1983-10-14       Impact factor: 4.432

Review 9.  Acetaminophen-induced hepatotoxicity.

Authors:  Laura P James; Philip R Mayeux; Jack A Hinson
Journal:  Drug Metab Dispos       Date:  2003-12       Impact factor: 3.922

10.  Lead poisoning from Asian traditional remedies in the West Midlands--report of a series of five cases.

Authors:  G R Bayly; R A Braithwaite; T M Sheehan; N H Dyer; C Grimley; R E Ferner
Journal:  Hum Exp Toxicol       Date:  1995-01       Impact factor: 2.903

View more
  8 in total

1.  Pharmacovigilance.

Authors:  I Ralph Edwards
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

3.  A manifesto for clinical pharmacology from principles to practice.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

4.  Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff.

Authors:  Munir Pirmohamed
Journal:  Wien Klin Wochenschr       Date:  2010-02       Impact factor: 1.704

5.  Adverse drug reactions.

Authors:  Yoon K Loke
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

6.  Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.

Authors:  Jeffrey K Aronson
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

7.  Causality Assessment in Pharmacovigilance: Still a Challenge.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

8.  The use of mechanistic evidence in drug approval.

Authors:  Jeffrey K Aronson; Adam La Caze; Michael P Kelly; Veli-Pekka Parkkinen; Jon Williamson
Journal:  J Eval Clin Pract       Date:  2018-06-11       Impact factor: 2.431

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.